July 28, 2022, AACC ended successfully in Chicago which can function like a lens to focus our attention on emerging science and clinical developments that are of contemporary importance. Clongene brought main products, such as infectious diseases, drugs of abuse, COVID-19 Antigen/Antibody Rapid Tests, as well as in vitro diagnostic reagents intended for other popular detected field to the exhibition.
COVID-19 rapid tests manufactured by Clongene have obtained authoritative certifications of CE and TGA. Since the spread of COVID-19, Clongene broadened production to meet the detection needs around the world. Based on the verification of German PEI, Swiss NAVI and British DHSC, which represent high quality of the products, and we won a number of popular marketing feedback from many countries.
Clongene started with the production of high-quality biological raw materials, and now we have expanded our business to in vitro diagnostic reagents, instruments and CRO&CDMO services. While continuously innovating the R&D of raw materials, we will keep being committed to product innovation and strict quality control.
